The Misclassification of Medical Marijuana

Total Page:16

File Type:pdf, Size:1020Kb

The Misclassification of Medical Marijuana REGULAR ARTICLE The Misclassification of Medical Marijuana Hannah Krystal, BA Marijuana has a complicated legal, social, and economic history in the United States, as well as an uncertain future. Marijuana has been consistently tied to racial minority groups since its arrival in the United States in the 1900s, and former Attorney General Jeff Sessions further propagated that notion. AG Sessions even recently wrote a memo that directly contradicted Obama-era policy, demonstrating that the current legal status of marijuana in both state and federal government is currently up for debate. While several states have legalized marijuana for medical or even recreational purposes, federal law still categorizes cannabis as a drug with no currently accepted medical use and a high potential for abuse. The comparison between marijuana, opioids, and ketamine in this article demonstrates that marijuana has been unnecessarily withheld and stigmatized by the federal government. Also reviewed is the impact of stringent marijuana- based legal policies upon the racial makeup of prison populations. The implications of current policy upon potential and future research are also discussed, with the determination that current policy has stymied research and prevented a more accurate determination of the risks and benefits of medical marijuana. J Am Acad Psychiatry Law 46:472–79, 2018. DOI:10.29158/JAAPL.003790-18 Marijuana has a complicated legal, social, and eco- ijuana on the basis of its unknown risks and lack of nomic history in the United States, and the issue of proven benefits despite the fact that synthetic canna- legalization has not yet been resolved. This article binoids have been demonstrated to elicit FDA- will comment upon the legal status of only medical approved benefits. marijuana, but it will discuss the potential risks of both medical and recreational marijuana to allay the Marijuana in the United States of fear that the legalization of medical marijuana poses a America: 1900–2018 significant threat to public health. While several states have legalized marijuana for medical or even Cannabis was initially marked as Schedule I for recreational purposes, federal law still categorizes reasons related to race and class. Other drugs were marijuana as a drug with no currently accepted med- associated with other racial minorities, such as the ical use and a high potential for abuse.1 While the mythical linkage between Chinese men, opium, and the seduction of white women that eventually led to legalization of medical marijuana in several states 3,4 prompted the federal government to reevaluate the the 1909 Opium Exclusion Act. Marijuana has status of marijuana, the U.S. Drug Enforcement Ad- been typically associated with negative racial stereo- types about both African Americans and Mexicans, ministration (DEA) reaffirmed the status of mari- 4 juana as a Schedule I drug in 2016, citing lack of as well as other Latin-American immigrants. The evidence of efficacy.2 This decision demonstrated, wave of anti-marijuana legislation that led to the cat- however, not a realistic evaluation of the risks and egorization of cannabis as a Schedule I drug dates benefits of marijuana, but a demonstration of the back to the early 1900s, when one member of the current catch-22 within American legal policy re- Texas Senate stated on the floor, “All Mexicans are garding marijuana: namely, that few risks have been crazy, and this [marijuana] is what makes them crazy.”5 California was the first state to prohibit mar- demonstrated and few benefits have been studied. 2 The federal government has restricted access to mar- ijuana in 1913, with Texas following suit in 1914. The federal government soon caught the anti-drug Ms. Krystal is a first-year medical student at the Icahn School of bug, and in 1915 the U.S. Secretary of Agriculture Medicine of Mount Sinai and is pursuing a Masters in Clinical used the 1906 Pure Food and Drug Act to declare Ethics from a joint program with Clarkson University. Address marijuana importation illegal based on the threat it correspondence to: Hannah Krystal, Icahn School of Medicine at 4,5 Mount Sinai, 2A-3 Aron Hall, 50 E. 98th St., New York, NY 10029. posed to health. A famous 1927 New York Times E-mail: [email protected] article entitled “Mexican Family Go Insane,” pro- Disclosures of financial or other potential conflicts of interest: None. posed that “a widow and her four children have been 472 The Journal of the American Academy of Psychiatry and the Law Krystal driven insane by eating the marihuana plant, accord- A Brief Discussion of the Schedule System 5 ing to doctors.” The period of 1933–1937, notably The federal government classifies drugs into sev- marked by the production of the infamous anti- eral different categories, known as Schedules I–V. cannabis film Reefer Madness in 1936, thus saw al- This article will largely focus on Schedules I–III. most every state enforce the Uniform Narcotic Drug Schedule I drugs are currently defined, as described Act, thereby increasing the strength of policing for above, as having no currently accepted medical use marijuana and other drugs.3,5 In 1937, Congress cre- and a high potential for abuse.1 Along with mari- ated the federal Marihuana Tax Act, which forbade 3 juana, heroin, lysergic acid diethylamide (LSD), 3,4- recreational and unlicensed use of cannabis. Later methylenedioxymethamphetamine (ecstasy), and laws established in 1951 and 1956 increased federal 1 control on marijuana and foreshadowed the estab- peyote have been classified as Schedule I. Cannabis lishment of the Comprehensive Drug Abuse and Pre- is not the only drug on this list to have potential vention and Control Act of 1970, better known as medical use; LSD, for example, has recently been considered for use as an antidepressant or the Controlled Substances Act, by the Nixon Admin- 12 istration.6 A former Nixon aide tied the Controlled anxiolytic. Substances Act directly to the politics of race, stating, Schedule II drugs, on the other hand, have at least “the Nixon White House . had two enemies: the one already proven, efficacious medical use, with “a antiwar left and African American people.... By high potential for abuse, with use potentially leading getting the public to associate the hippies with mar- to severe psychological or physical dependence. 1 ijuana and African Americans with heroin, and then These drugs are also considered dangerous.” Sched- criminalizing both heavily, we could disrupt those ule II includes some unexpected drugs, such as co- communities.”7 Since the 1970s, the scheduling of caine and crystal methamphetamine, as well as most drugs into different risk-based categories has pre- opioids, amphetamine/dextroamphetine salts (Ad- sented various ethics, legal, and medical issues. While derall™), and methylphenidate (Ritalin™).1 Co- the Controlled Substances Act has worked to fight caine is a Schedule II drug because of its approved drug abuse and addiction, marijuana does not pres- medical use as a local anesthetic, despite its lengthy ent the high risk level of a Schedule I drug and should history of abuse;6 methamphetamines can suppress not be classified as such. appetite in obese patients and are legally prescribed Attorney General Sessions started to reverse to stabilize severe attention-deficit hyperactivity dis- Obama-era policies that allowed for the state-by- order (ADHD) symptoms in children over the age of state legalization of medical marijuana. In 2013, six.13 AdderallTM can be prescribed to children ages then-Deputy Attorney General James Cole issued a three or above.14 Nabilone (Cesamet™), a synthetic memo limiting prosecution to “the most significant oral cannabinoid derived from marijuana, has also threats in the most effective, consistent, and rational been classified as Schedule II due to its use as an 8 way.” Essentially, Deputy AG Cole encouraged the antiemetic.15 federal government to leave the regulation of medical Finally, Schedule III drugs maintain “a moder- and recreational marijuana to the states that imple- ate to low potential for physical and psychological mented policies of legalization.8 Following this shift dependence. Schedule III drugs abuse [sic] poten- in federal policy, a bipartisan bill was proposed by tial is less than Schedule I and Schedule II drugs Florida senators Matt Gaetz (Republican) and Dar- 1 ren Soto (Democrat) in April 2017 to recategorize but more than Schedule IV.” Schedule III drugs 9 include ketamine, testosterone, and anabolic ste- marijuana as a Schedule III drug. A January 4, 2018, 1 memo written by AG Sessions, however, essentially roids. A second synthetic cannabinoid and reneged on the Obama-era policy.10 This new memo marijuana derivative, dronabinol (Marinol™), re- directly contradicted the Deputy AG Cole’s memo, sides on the list of Schedule III drugs for its use as 16 although it did not contradict a later memo from an appetite stimulant and antiemetic. The fed- 2014 discouraging the prosecution of money made erally defined schedules have been enumerated from the sale of legal marijuana.10,11 Because of AG here to provide a context for the comparison Sessions’ stance on cannabis, the future of medical among the schedules of marijuana, opioids, and marijuana in the United States is currently uncertain. ketamine. Volume 46, Number 4, 2018 473 The Misclassification of Medical Marijuana Marijuana, Opioids, and Ketamine: Side ijuana presents less potential for abuse than ketamine Effects and less risk of addiction
Recommended publications
  • Clearing the Smoke on Cannabis: Regular Use and Cognitive Functioning
    6 Clearing the Smoke on Cannabis Regular Use and Cognitive Functioning Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Amy Porath, Ph.D., Director, Research, CCSA Key Points • Regular use refers to weekly or more frequent cannabis use over a period of months to years. Regular cannabis use is associated with mild cognitive difficulties, which are typically not apparent following about one month of abstinence. Heavy (daily) and long-term cannabis use is related to more This is the first in a series of reports noticeable cognitive impairment. that reviews the effects of cannabis • Cannabis use beginning prior to the age of 16 or 17 is one of the strongest use on various aspects of human predictors of cognitive impairment. However, it is unclear which comes functioning and development. This first — whether cognitive impairment leads to early onset cannabis use or report on the effects of chronic whether beginning cannabis use early in life causes a progressive decline in cannabis use on cognitive functioning cognitive abilities. provides an update of a previous report • Regular cannabis use is associated with altered brain structure and function. with new research findings that validate Once again, it is currently unclear whether chronic cannabis exposure and extend our current understanding directly leads to brain changes or whether differences in brain structure of this issue. Other reports in this precede the onset of chronic cannabis use. series address the link between chronic • Individuals with reduced executive function and maladaptive (risky and cannabis use and mental health, the impulsive) decision making are more likely to develop problematic cannabis use and cannabis use disorder.
    [Show full text]
  • Medical Cannabis Q&A
    Medical Cannabis Q&A 1. What is medical cannabis? The term “medical cannabis” is used to describe products derived from the whole cannabis plant or its extracts containing a variety of active cannabinoids and terpenes, which patients take for medical reasons, after interacting with and obtaining authorization from their health care practitioner. 2. What are the main active ingredients? The chemical ingredients of cannabis are called cannabinoids. The two main therapeutic ones are: THC:CBD a. Tetrahydrocannabinol (THC) is a partial agonist of CB1 and CB2 receptors. It is psychoactive and produces the euphoric effect. Each cannabis product will contain THC and CBD, however b. Cannabidiol (CBD) has a weak affinity for CB1 and CB2 receptors and appears the THC: CBD ratio will differ to exert its activity by enhancing the positive effects of the body’s endogenous depending on the product. cannabinoids. 3. Why do patients take it? Medical cannabis may be used to alleviate symptoms for a variety of conditions. It has most commonly been used in neuropathic pain and other chronic pain conditions. There is limited, but developing clinical evidence surrounding its safety and efficacy, and it does not currently have an approved Health Canada indication. 4. How do patients take it? Cannabis can be smoked, vaporized, taken orally, sublingually, topically or rectally. Different routes of administration will result in different pharmacokinetic and pharmacodynamic properties of the drug. 5. Is it possible to develop dependence on medical cannabis? Yes, abrupt discontinuation after long-term use may result in withdrawal symptoms. Additionally, chronic use may result in psychological dependence.
    [Show full text]
  • Part 4: Justification: Children, Drug Use, and Dependence
    Part 4: Justification: Children, Drug Use, and Dependence Part 4 focuses on the policy justification of protecting people, especially children, from the harmful effects of drugs, including drug dependence. This premise is not challenged. Let us take it as read, and agreed by all, that it is not a good idea for children to use drugs, and that the use of drugs at an early age can be especially harmful— physically, socially, and psychologically.1 This is clear from a number of the chapters in this section. But policies aimed at dealing with this concern must be interrogated. Is the desire to protect children from drug use and dependence justification for the measures that have been adopted? And what does a closer look say about future strategies? In this section, five very different chapters ask searching questions of the policy responses that have been put in place to deal with drug use among children and young people, and of some of the assumptions underlying prevailing views of drugs, drug use, and dependence. The first chapter in this section is “Youth Drug-Use Research and the Missing Pieces in the Puzzle: How Can Researchers Support the Next Generation of Harm Reduction Approaches?” by Catherine Cook and Adam Fletcher. The chapter cuts to the root of this central justification for the war on drugs, challenging what we really know and do not know about drug use among young people.2 It explores the extent of our knowledge regarding drug use among young people around the world, concluding that far too little is known about emerging patterns of drug use in low- and middle-income countries, rendering the global picture incomplete.
    [Show full text]
  • 2020 DAID Conference Tentative Schedule and Agenda Online
    Tentative 2020 Conference Schedule (As of 7/24/20) Please note that this schedule is suBject to change All times are EST 2020 Conference Schedule Thursday, August 6, 2020 11:00 AM 12:00 PM Opening Ceremony & Keynote Presentation 12:00 PM 12:45 PM Exposition Hall & Networking Linking SFST Impairment to Individual What You Need to Know About Today's Drug Do You Have Skin in the Game? 12:45 PM 1:45 PM Driving Tasks Mule James Camp Travis Herbert Mike Snyders & Tim Cardwell 1:45 PM 2:00 PM Break To Draw or Not to Draw: Why Your DRE Traditional and Designer Benzodiazepines Building Your DRE Program Through Program Should Include LE Phlebotomists 2:00 PM 3:00 PM in Impaired Driving Casework Education and Awareness Jennifer Cifaldi, Nicholas Knoll, & Kemp Dr. Barry Logan & Ayako Hosokawa Frank Enko Layden 3:00 PM 3:15 PM Break Overcoming Defense Challenges 3:15 PM 4:45 PM Clay Abbott, Beth Barnes, & Jeff SIfers 4:45 PM 5:30 PM Networking Discussions on Contemporary Issues Friday, August 7, 2020 Public-Private Ventures, Curbing Alcohol Traffic Safety as a Critical Part of an Agency's NHTSA Update 11:00 AM 12:00 PM and Drug Impaired Driving Patrol Strategy Amy Berning, Bill O'Leary, & Christine Frank Ed Hutchison, John Whetsel, & Glenn Davis Howard Hall & Cara Jacobs 12:00 PM 1:00 PM Exposition Hall & Networking Beyond Eye Movements: How Intoxication Affects Visual Perception 1:00 PM 2:15 PM Dr. Karl Citek 2:15 PM 2:30 PM Break Responsibility.org: A Proactive Partner in Eliminating Impaired Driving/Safe Night Take a Breath and Reconstruct Winning the Case with Testimony 2:30 PM 3:30 PM Out Chuck Matson Christine Circo Darrin Grondel & John Mastoras 3:30 PM 3:45 PM Break Courtroom Testimony from a Judge's Dusted in Houston: Spike in PCP-Driving Noteworthy Supreme Court Cases 3:45 PM 4:45 PM Perspective Cases Kendrick Stecker Hon.
    [Show full text]
  • Drug Education and Its Publics in 1980S Britain
    International Journal of Drug Policy 88 (2021) 103029 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locate/drugpo Policy Analysis Just say know: Drug education and its publics in 1980s Britain Alex Mold Centre for History in Public Health, London School of Hygiene & Tropical Medicine, 15-17 Tavistock Place, London, WC1H 9SH, United Kingdom ARTICLE INFO ABSTRACT Keywords: Until the 1980s, anti-drug education campaigns in the UK were rare. This article examines the reasons behind a Heroin policy shift that led to the introduction of mass media drug education in the mid 1980s. It focuses on two Drug education campaigns. ‘Heroin Screws You Up’ ran in England, and ‘Choose Life Not Drugs’ ran in Scotland. The campaigns Health education were different in tone, with ‘Heroin Screws You Up’ making use of fear and ‘shock horror’ tactics, whereas History of drug use ‘Choose Life Not Drugs’ attempted to deliver a more positive health message. ‘Heroin Screws You Up’ was criticised by many experts for its stigmatising approach. ‘Choose Life Not Drugs’ was more favourably received, but both campaigns ran into difficulties with the wider public. The messages of these campaigns were appro­ priated and deliberately subverted by some audiences. This historical policy analysis points towards a complex and nuanced relationship between drug education campaigns and their audiences, which raises wider questions about health education and its ‘publics’. In April 1986, the cast of teen TV soap, Grange Hill, released a song wanted to be seen to take action on drugs, leading to the introduction of titled ‘Just say no’.
    [Show full text]
  • An Investigation of the Acute and Chronic Effects of Ketamine on Cognition
    An Investigation of the Acute and Chronic Effects of Ketamine on Cognition Celia J.A. Morgan University College London Submitted for the degree of Doctor of Philosophy University of London May 2005 l UMI Number: U593077 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U593077 Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract The work presented in this thesis aimed to investigate the consequences and causes of ketamine abuse and compare them with the acute effects of the drug. Seven experimental chapters report the findings of a total of 9 studies: 5 with ketamine users, 3 administering ketamine to healthy volunteers and 1 with psychosis-prone individuals. Acute studies with volunteers demonstrated ketamine-induced impairments to item recognition, source memory, controlled semantic processing, working memory and procedural learning. There was also a suggestion of a disruption in self-monitoring but perceptual priming and executive functioning were largely preserved. Ketamine was subjectively reinforcing in healthy volunteers. Suggested chronic effects of ketamine in drug users included deficits in source memory and controlled semantic processing indicative of a degraded semantic store.
    [Show full text]
  • Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C
    NEW JERSEY CANNABIS REGULATORY COMMISSION Personal Use Cannabis Rules Special Adopted New Rules: N.J.A.C. 17:30 Adopted: August 19, 2021 by New Jersey Cannabis Regulatory Commission, Dianna Houenou, Chair. Filed: August 19, 2021 Authority: N.J.S.A. 24:6I-31 et seq. Effective Date: August 19, 2021 Expiration Date: August 19, 2022 This rule may be viewed or downloaded from the Commission’s website at nj.gov/cannabis. These rules are adopted pursuant to N.J.S.A. 24:6I-34(d)1a of the New Jersey Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, N.J.S.A. 24:6I- 31 et seq., and became effective upon acceptance for filing by the Office of Administrative Law. The specially adopted new rules shall be effective for a period not to exceed one year from the date of filing of the new rules, that is, until August 19, 2022. The Commission has provided this special adoption to the Attorney General, State Treasurer, Commissioner of Health, and Commissioner of Banking and Insurance for a consultation period, after which the Commission anticipates filing a proposal to readopt these rules with amendments reflecting the results of that consultation. In accordance with N.J.S.A. 24:6I-34(d)1b the rules, as readopted, will become effective upon acceptance for filing by the Office of Administrative Law if filed on or before the expiration date of the rules published herein. The adopted amendments will be effective upon publication in the New Jersey Register. Federal Standards Analysis The Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act obliges the Cannabis Regulatory Commission to promulgate rules necessary or proper to enable it to carry out the Commission’s duties, functions, and powers with respect to overseeing the development, regulation, and enforcement of activities associated with the personal use of cannabis pursuant to P.L.2021, c.16.
    [Show full text]
  • Legalization and Decriminalization of Cannabis |
    AMERICAN MEDICAL ASSOCIATION YOUNG PHYSICIANS SECTION Resolution: 5 (A-19) Introduced by: Albert L. Hsu, MD Subject: Public Health Impacts and Unintended Consequences of Legalization and Decriminalization of Cannabis for Medicinal and Recreational Use Referred to: AMA-YPS Reference Committee 1 Whereas, AMA Policy D-95.969, “Cannabis Legalization for Medicinal Use,” states, in part, that 2 our AMA: “(2) believes that cannabis for medicinal use should not be legalized through the state 3 legislative, ballot initiative, or referendum process;” and 4 5 Whereas, AMA Policy H-95.924, “Cannabis Legalization for Recreational Use,” states, in part, 6 that our AMA: “(5) encourages local, state, and federal public health agencies to improve 7 surveillance efforts to ensure data is available on the short- and long-term health effects of 8 cannabis use;” and 9 10 Whereas, AMA Policy H-95.923, “Taxes on Cannabis Products,” states that “our AMA 11 encourages states and territories to allocate a substantial portion of their cannabis tax revenue 12 for public health purposes, including: substance abuse prevention and treatment programs, 13 cannabis-related educational campaigns, scientifically rigorous research on the health effects of 14 cannabis, and public health surveillance efforts;” and 15 16 Whereas, AMA Policy H-95.952, “Cannabis and Cannabinoid Research,” states, in part, that our 17 AMA: “(4) supports research to determine the consequences of long-term cannabis use, 18 especially among youth, adolescents, pregnant women, and women who are breastfeeding;
    [Show full text]
  • Important Information and Warnings About Using Medical Cannabis
    Important information and warnings about using medical cannabis Use of medical cannabis products is experimental Use of medical cannabis products may or may not relieve your symptoms. Existing studies of medical cannabis suggest symptom relief can vary from patient to patient. Side effects are very common. Among the most common side effects are dizziness, fatigue, dry mouth, light- headedness, drowsiness, and nausea. Side effects are usually mild to moderate in severity and usually resolve quickly, but occasionally severe side effects occur. There are unknown each time a patient starts taking any new medication and these unknowns are particularly prominent for medical cannabis, which is not approved for use by the Food and Drug Administration. For most condition, more study of medical cannabis is needed to understand its proper role in comprehensive medical care. Tell all your health care professionals about the medical cannabis you are using Medical cannabis can interfere with other drugs you are taking. Make sure to tell all your health care professionals about the medical cannabis you are taking. Blood levels of other medications might need to be checked, and doses of the medications might need to be adjusted. Warning The following groups are believed to be at increased risk of harm from use of cannabis. Persons in these groups should generally not use medical cannabis • Children, adolescents, and you adults • Women who are pregnant and breastfeeding • Persons with personal or family history of psychotic disorder such as schizophrenia
    [Show full text]
  • Clearing the Smoke on Cannabis: Regular Use and Mental Health
    1 Clearing the Smoke on Cannabis Regular Use and Mental Health Sarah Konefal, Ph.D., Research and Policy Analyst, CCSA Robert Gabrys, Ph.D., Research and Policy Analyst, CCSA Amy Porath, Ph.D., Director, Research, CCSA Key Points • Regular cannabis use refers to weekly or more frequent cannabis use over a period of months to years. • Regular cannabis use is at least twice as common among individuals with This is the first in a series of reports mental disorders, including schizophrenia, bipolar disorders, depressive and that reviews the effects of cannabis anxiety disorders, and post-traumatic stress disorder (PTSD). use on various aspects of human • There is strong evidence linking chronic cannabis use to increased risk of developing psychosis and schizophrenia among individuals with a family functioning and development. This history of these conditions. report on the effects of regular • Although smaller, there is still a risk of developing psychosis and cannabis use on mental health provides schizophrenia with regular cannabis use among individuals without a family an update of a previous report with history of these disorders. Other factors contributing to increased risk of new research findings that validate and developing psychosis and schizophrenia are early initiation of use, heavy or extend our current understanding of daily use and the use of products high in THC content. this issue. Other reports in this series • The risk of developing a first depressive episode among individuals who use address the link between regular cannabis regularly is small after accounting for the use of other substances cannabis use and cognitive functioning, and common sociodemographic factors.
    [Show full text]
  • (A-9-THC) Content in Herbal Cannabis Over Time
    32 Current Drug Abuse Reviews, 2012, 5, 32-40 Increasing Delta-9-Tetrahydrocannabinol (-9-THC) Content in Herbal Cannabis Over Time: Systematic Review and Meta-Analysis Fidelia Cascini*,1, Carola Aiello2 and GianLuca Di Tanna3 1Istituto di Medicina Legale, Università Cattolica del S. Cuore, largo F. Vito, 1 00168 Roma, Italy 2Department of Informatics and Systemics, University ‘La Sapienza’, 00185 Rome, Italy 3Department of Public Health and Infectious Diseases, University "La Sapienza", 00185, Rome, Italy Abstract: Aim: The objective of this meta-analysis is to assess the data regarding changes in herbal cannabis potency over time (from 1970 to 2009). Methods: Systematic searches of 17 electronic scientific databases identified studies on this topic, within which 21 case series studies satisfied our inclusion criteria of reporting the mean tetrahydrocannabinol (THC) value per number of samples per year. No language, publication date, publication type or status restrictions were imposed. The study selection and data extraction processes were performed independently but uniformly by two authors, included screening, determination of eligibility and inclusion of the eligible studies in the systematic review, and a meta-analysis of the results on THC content in herbal cannabis samples. We considered papers and not monographic scientific publications, rejecting all studies that were not focused on the subject of this review. Results: Meta-analysis by year was performed on 21 studies containing 75 total mean THC observations from 1979 to 2009 using the random effects model. The results revealed much variability between studies. Further, there was a significant correlation between year and mean THC in herbal cannabis. The combined data indicated the correlation between year and mean THC in herbal cannabis, revealing a temporal trend of increasing potency (5% above the mean THC value in the Poisson regression analysis).
    [Show full text]
  • Downloaded from by Pediatricsguest on October Vol.3, 2021 109 No
    Just a Click Away: Recreational Drug Web Sites on the Internet Paul M. Wax, MD ABSTRACT. The explosive growth of the Internet in sharp rise in MDMA use among college students as recent years has provided a revolutionary new means of well.3 The report of the Drug Abuse Warning Net- interpersonal communication and connectivity. Informa- work released in December 2000 reveals that emer- tion on recreational drugs—once limited to bookstores, gency department (ED) episodes related to MDMA, libraries, mass media, and personal contacts—is now GHB, and ketamine increased significantly during readily available to just about anyone with Internet ac- 4 cess. Not surprising, Internet access greatly facilitates the the period 1994 to 1999. In addition, abuse of some free and easy exchange of ideas, opinions, and unedited older drugs, such as dextromethorphan, seems to be 5 and nonrefereed information about recreational drugs. on the upsurge. This article presents a patient who came to medical at- Simultaneous with this “club” drug revolution has tention as the result of recreational drug-taking behavior been the explosive growth of the Internet. A dra- directly influenced by her Internet browsing. A second matic change in the everyday means of communica- case is presented in which the only information available tions has taken place. E-mail is now ubiquitous, and about the medical effects of a new “designer” drug was the World Wide Web, known as the Internet, brings found on a recreational drug Internet Web site. Several people together from all over the world attracted by such Web sites are described in detail.
    [Show full text]